Phototoxic eruption secondary to doxycycline treatment for MEK inhibitor-induced acneiform dermatitis.

Authors

  • R.N.H. Seervai Providence Portland Medical Center, Portland, Oregon https://orcid.org/0000-0001-7210-8350
  • S.L. Ophaug Oregon Health and Science University, Portland, Oregon, USA
  • J. Dhossche Oregon Health and Science University, Portland, Oregon, USA
  • C. Conrady Oregon Health and Science University, Portland, Oregon, USA
  • M.B. Miller Oregon Health and Science University, Portland, Oregon, USA
  • S.L. Leitenberger Oregon Health and Science University, Portland, Oregon, USA

DOI:

https://doi.org/10.26326/2281-9649.32.4.2404

Keywords:

MEK, pilocytic astrocytoma, doxycycline, acne, phototoxicity

Abstract

Acneiform rash is the most common dermatologic toxicity associated with small-molecule inhibitors (Nibs) targeting the MAPK/ERK kinase MEK. Here, we present the case of a patient with pilocytic astrocytoma who developed a phototoxic eruption after doxycycline treatment for trametinib-induced acneiform rash, requiring discontinuation of her cancer therapy. Photosensitivity reactions associated with Nibs are unrelated to their kinase activity. We propose use of doxycycline as the indirect mechanism linking this type of dermatologic toxicity in pediatric cancer patients receiving MEK inhibitor therapy.

Downloads

Published

2022-11-21

How to Cite

Seervai, R., Ophaug, S., Dhossche, J., Conrady, C., Miller, M., & Leitenberger, S. (2022). Phototoxic eruption secondary to doxycycline treatment for MEK inhibitor-induced acneiform dermatitis. European Journal of Pediatric Dermatology, 32(4), 222–6. https://doi.org/10.26326/2281-9649.32.4.2404

Issue

Vol. 32 No. 4 (2022)

Section

Original articles